For patients with advanced solid tumors harboring specific genetic alterations, the first-in-class synthetic lethal combination of WEE1 inhibitor zedoresertib plus PKMYT1 inhibitor lunresertib demonstrated promising antitumor activity and was generally well-tolerated, according to Phase I MYTHIC trial data reported by researchers at The University of Texas MD Anderson Cancer Center.

AI summaries can be wrong sometimes—always verify important details using the source link below.